OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
10
Results
Show all
Save search
Copy query
Show results for
Unknown
(10)
Publication Date
Release Date
2018
(3)
2016
(3)
2015
(2)
2019
(1)
2017
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.
Not available
S-EPMC4369830
|
biostudies-literature
Cite
Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial.
Not available
S-EPMC5786132
|
biostudies-literature
Cite
Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial.
Not available
S-EPMC6069824
|
biostudies-literature
Cite
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Not available
S-EPMC5342029
|
biostudies-literature
Cite
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Not available
S-EPMC4936193
|
biostudies-literature
Cite
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Not available
S-EPMC4576908
|
biostudies-literature
Cite
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
Not available
S-EPMC4872363
|
biostudies-literature
Cite
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
Not available
S-EPMC5485075
|
biostudies-literature
Cite
The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).
Not available
S-EPMC6398702
|
biostudies-literature
Cite
Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study.
Not available
S-EPMC5883294
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets